PMID- 18054742
OWN - NLM
STAT- MEDLINE
DCOM- 20080226
LR  - 20111117
IS  - 1521-690X (Print)
IS  - 1521-690X (Linking)
VI  - 21
IP  - 4
DP  - 2007 Dec
TI  - PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
PG  - 687-710
AB  - Patients with type-2 diabetes mellitus (T2DM) are considered to be at 
      particularly high risk for cardiovascular disease. Over the last decade, the 
      members of the peroxisome proliferator-activated receptor (PPAR) subfamily of 
      nuclear receptors have emerged as valuable pharmacological targets whose 
      activation can normalize metabolic dysfunctions and reduce some cardiovascular 
      risk factors associated with T2DM. PPARalpha agonists, such as the fibrates, can 
      correct dyslipidemia. PPARgamma agonists, such as the thiazolidinediones, act as 
      insulin sensitizers and improve insulin resistance in patients with T2DM. Because 
      of restricted potency and certain side-effects of PPAR agonists, as well as the 
      increasingly epidemic incidence of T2DM, there is a real need for the development 
      of selective PPAR agonists with improved clinical efficacy. This chapter focuses 
      on the PPAR agonists currently used in the clinic, as well as on the discovery 
      and development of the next generation of PPAR agonists.
FAU - Gross, Barbara
AU  - Gross B
AD  - Institut Pasteur de Lille, 1 rue du Prof Calmette, Lille, F-59019, France.
FAU - Staels, Bart
AU  - Staels B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Endocrinol Metab
JT  - Best practice & research. Clinical endocrinology & metabolism
JID - 101120682
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 0 (Lipoproteins)
RN  - 0 (PPAR alpha)
RN  - 0 (PPAR delta)
RN  - 0 (PPAR gamma)
RN  - 0 (Peroxisome Proliferator-Activated Receptors)
RN  - 0 (Thiazolidines)
SB  - IM
MH  - Animals
MH  - Blood Glucose/metabolism
MH  - Cardiovascular Diseases/prevention & control
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Homeostasis/drug effects
MH  - Humans
MH  - Insulin/physiology
MH  - Insulin Resistance/physiology
MH  - Lipid Metabolism/drug effects
MH  - Lipoproteins/metabolism
MH  - PPAR alpha/agonists/physiology
MH  - PPAR delta/agonists/physiology
MH  - PPAR gamma/agonists/physiology
MH  - Peroxisome Proliferator-Activated Receptors/*agonists
MH  - Thiazolidines/pharmacology
RF  - 108
EDAT- 2007/12/07 09:00
MHDA- 2008/02/27 09:00
CRDT- 2007/12/07 09:00
PHST- 2007/12/07 09:00 [pubmed]
PHST- 2008/02/27 09:00 [medline]
PHST- 2007/12/07 09:00 [entrez]
AID - S1521-690X(07)00088-7 [pii]
AID - 10.1016/j.beem.2007.09.004 [doi]
PST - ppublish
SO  - Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):687-710. doi: 
      10.1016/j.beem.2007.09.004.